GAITHERSBURG, Md., Feb. 21, 2022 /PRNewswire/ -- Novavax, Inc.
(Nasdaq: NVAX), a biotechnology company dedicated to developing and
commercializing next-generation vaccines for serious infectious
diseases, today announced it will report its fourth quarter and
full year 2021 financial results and operational highlights on
Monday, February 28, 2022, following
the close of U.S. financial markets. Details of the event and
replay are as follows:
|
Conference call
details:
|
|
Date:
|
February 28,
2022
|
|
Time:
|
4:30 p.m. U.S.
Eastern Standard Time (EST)
|
|
Dial-in
number:
|
(877)
870-4263 (Domestic) or (412) 317-0790
(International)
|
|
Webcast:
|
www.novavax.com/events
|
|
•
|
Participants will
be prompted to request to join the Novavax, Inc.
call.
|
|
•
|
To ensure a timely
connection, it is recommended that participants join at least 10
minutes prior to the scheduled webcast.
|
|
|
|
Replay
details:
|
|
Date:
|
Available starting at
7:30 p.m. EST, February 28, 2022 until 11:59 p.m. EST, March 7,
2022
|
|
Dial-in
number:
|
(877) 344-7529
(Domestic) or (412) 317-0088 (International)
|
|
Passcode:
|
2206365
|
|
Webcast:
|
www.novavax.com/events, until May 28, 2022
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that
promotes improved health globally through the discovery,
development and commercialization of innovative vaccines to prevent
serious infectious diseases. The company's proprietary recombinant
technology platform harnesses the power and speed of genetic
engineering to efficiently produce highly immunogenic nanoparticles
designed to address urgent global health needs. NVX-CoV2373, the
company's COVID-19 vaccine, has received conditional authorization
from multiple regulatory authorities globally, including the
European Commission and the World Health Organization. The vaccine
is also under review by multiple regulatory agencies worldwide. In
addition to its COVID-19 vaccine, Novavax is also currently
evaluating a COVID-seasonal influenza combination vaccine in a
Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu,
its quadrivalent influenza investigational vaccine candidate. These
vaccine candidates incorporate Novavax' proprietary saponin-based
Matrix-M™ adjuvant to enhance the immune response and stimulate
high levels of neutralizing antibodies.
For more information, visit www.novavax.com and
connect with us on Twitter, LinkedIn, Instagram and
Facebook.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2021-financial-results-and-operational-highlights-on-february-28-2022-301486788.html
SOURCE Novavax, Inc.